Bridgepoint Group (LON:BPT) Upgraded at Citigroup

Citigroup upgraded shares of Bridgepoint Group (LON:BPT) to a buy rating in a research report released on Thursday morning, Marketbeat reports. Citigroup currently has GBX 410 ($5.29) target price on the stock.

Bridgepoint Group Price Performance

BPT opened at GBX 328.40 ($4.24) on Thursday. The stock has a market cap of £2.71 billion, a price-to-earnings ratio of 59.66, a PEG ratio of 0.61 and a beta of 1.72. The stock has a fifty day moving average price of GBX 358.93 and a 200 day moving average price of GBX 346.57. The company has a current ratio of 4.98, a quick ratio of 3.60 and a debt-to-equity ratio of 12.89. Bridgepoint Group has a 1 year low of GBX 202.40 ($2.61) and a 1 year high of GBX 410 ($5.29).

Bridgepoint Group (LON:BPT) last issued its quarterly earnings data on Thursday, March 13th. The company reported GBX 19.50 ($0.25) EPS for the quarter. Bridgepoint Group had a net margin of 16.74% and a return on equity of 6.10%. Analysts forecast that Bridgepoint Group will post 17.4062165 EPS for the current fiscal year.

Bridgepoint Group Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Thursday, May 22nd. Shareholders of record on Thursday, April 24th will be given a GBX 4.60 ($0.06) dividend. This represents a yield of 1.43%. The ex-dividend date is Thursday, April 24th. Bridgepoint Group’s payout ratio is presently 163.50%.

About Bridgepoint Group

Bridgepoint Group plc is a private equity and private credit firm specializing in middle market, small mid cap, small cap, growth capital, buyouts investments, syndicate debt, infrastructure, direct lending and credit opportunities in private credit investments. It prefers to invest in advanced industrials, automation, agricultural sciences, energy transition enablers, business services, financial services, professional services, testing inspection and certification, information services, consumer, digital brands, video games, wellbeing products, health care, pharma and MedTech outsourced services, pharma products, and MedTech Products sectors.